A single centre, randomised, double-blind, double-dummy, placebo-and active-controlled, 3-way cross-over study to evaluate the 24 hour FEV1 profile of a single dose of CHF 5188 pMDI (400/4 mcg QD) (fixed combination budesonide/carmoterol 200/2 mcg) in adults patients with moderate or severe persistent asthma.

Trial Profile

A single centre, randomised, double-blind, double-dummy, placebo-and active-controlled, 3-way cross-over study to evaluate the 24 hour FEV1 profile of a single dose of CHF 5188 pMDI (400/4 mcg QD) (fixed combination budesonide/carmoterol 200/2 mcg) in adults patients with moderate or severe persistent asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Budesonide/carmoterol; Budesonide/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top